Lung cancer prognosis has traditionally been determined by tumour burden. For decades, the principal determinant of outcome after surgical resection has been pathological stage, defined according to the International Association for the Study of Lung Cancer tumour-node-metastasis classification, now in its ninth edition.
Despite this progress, precision medicine has remained largely tumour-centric. Patient characteristics including pulmonary function, performance status, frailty and comorbidity have been used to determine fitness for treatment rather than long-term prognosis. As our understanding of tumour biology…